CMA mediates resistance in breast cancer models

Alessia Lo Dico; C Martelli; F Corsi; D Porro; L Ottobrini; G Bertoli

doi:10.1186/s12935-023-02969-9

CMA mediates resistance in breast cancer models

Cancer Cell Int. 2023 Jul 5;23(1):133. doi: 10.1186/s12935-023-02969-9.

Authors

Alessia Lo Dico^{1

2}, C Martelli³, F Corsi^{4

5}, D Porro^{1

2}, L Ottobrini^#^{6

7}, G Bertoli^#^{8

9}

Affiliations

¹ Molecular Bioimaging and Physiology (IBFM), CNR, Segrate, Milan, Italy.
² NBFC, National Biodiversity Future Center, Palermo, Italy.
³ Department of Pathophysiology and Transplantation, University of Milan, Segrate, Milan, Italy.
⁴ Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy.
⁵ Surgery Department, Istituti Clinici Scientifici Maugeri IRCCS, Pavia, Italy.
⁶ Molecular Bioimaging and Physiology (IBFM), CNR, Segrate, Milan, Italy. luisa.ottobrini@unimi.it.
⁷ Department of Pathophysiology and Transplantation, University of Milan, Segrate, Milan, Italy. luisa.ottobrini@unimi.it.
⁸ Molecular Bioimaging and Physiology (IBFM), CNR, Segrate, Milan, Italy. gloria.bertoli@ibfm.cnr.it.
⁹ NBFC, National Biodiversity Future Center, Palermo, Italy. gloria.bertoli@ibfm.cnr.it.

^# Contributed equally.

Abstract

Background: Breast cancer (BC) is the most common malignancy in women and the second leading cause of cancer-related death; chemoresistance is still a clinical challenge mainly because of the different molecular features of this kind of tumour. Doxorubicin (Doxo) is widely used despite its adverse effects and the common onset of resistance. Chaperone-Mediated Autophagy (CMA) has been identified as an important mechanism through which chemotherapeutics can exert their cytotoxic effects and, in this context, LAMP-2A, the key player of CMA, can be a useful biomarker.

Methods: A cohort of patients and breast cancer cells have been screened for Doxo effect and CMA activation by analysing the LAMP-2A level. Molecular silencing has been used to clarify CMA role in BC responsiveness to treatments. Low Doxo doses were combined with other drugs (TMZ or PX-478, a HIF-1α inhibitor) to evaluate their cytotoxic ability and their role in modulating CMA.

Results: In this paper, we showed that CMA is an important mechanism mediating the responsiveness of breast cancer cell to different treatments (Doxo and TMZ, as suggested by triple negative cells that are TMZ-resistant and fails to activate CMA). The LAMP-2A expression level was specific for different cell lines and patient-derived tumour subtypes, and was also useful in discriminating patients for their survival rates. Moreover, molecular silencing or pharmacological blockage of HIF-1α activity reverted BC resistance to TMZ. The combination of low-dose Doxo with TMZ or PX-478 showed that the drug associations have synergistic behaviours.

Conclusion: Here, we demonstrated that CMA activity exerts a fundamental role in the responsiveness to different treatments, and LAMP-2A can be proposed as a reliable prognostic biomarker in breast cancer. In this context, HIF-1α, a potential target of CMA, can also be assessed as a valuable therapeutic target in BC in view of identifying new, more efficient and less toxic therapeutic drug combinations. Moreover, the possibility to combine Doxo with other drugs acting on different but coherent molecular targets could help overcome resistance and open the way to a decrease in the dose of the single drugs.

Keywords: Chaperone-mediated autophagy (CMA); Doxorubicin (Doxo); HER2+ breast cancer; Luminal A breast cancer; Luminal B breast cancer; Temozolomide (TMZ); Triple negative breast cancer.

Abstract

Grants and funding